Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02262455 · ClinicalTrials.gov registry record · Phase 1
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Santa Maria Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT02262455: Completed Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Santa Maria Biotherapeutics.
NCT02262455 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that has completed, run by Santa Maria Biotherapeutics. The registered enrollment target is 32 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02262455, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, has completed, sponsored by Santa Maria Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
Primary Outcome
To define the maximum tolerated dose (MTD) of STM 434 administered alone or in combination with liposomal doxorubicin chemotherapy in patients with ovarian cancer or other advanced solid tumors.
Conditions Studied
Interventions
- DRUG Liposomal doxorubicin
- DRUG STM 434
Study Locations (4)
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-01-13 |
| Phase | Phase 1 |
What the finished NCT02262455 record still lists
NCT02262455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Liposomal doxorubicin is the first listed.
NCT02262455 reports a single indexed study location in Massachusetts, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02262455 about?
NCT02262455 is a clinical study titled "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors". This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
What is the current status of trial NCT02262455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-10. Estimated completion is 2017-01-13.
What conditions does trial NCT02262455 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Solid Tumors, Fallopian Tube Cancer.
What interventions are being tested in trial NCT02262455?
The interventions under investigation include: Liposomal doxorubicin (DRUG), STM 434 (DRUG).
Who is sponsoring clinical trial NCT02262455?
This trial is sponsored by Santa Maria Biotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02262455 being conducted?
This trial has 4 study locations across Massachusetts, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02262455's enrollment target sits among peer trials
32 249th of 322 higher than 73 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia